Viral Protein Patents (Class 536/23.72)
  • Patent number: 10227569
    Abstract: In certain embodiments, the disclosure relates to vectors containing bacterial nucleic acid sequences and a paramyxovirus gene. Typically, the expression vector comprises a bacterial artificial chromosome (BAC), and a nucleic acid sequence comprising a respiratory syncytial virus (RSV) gene in operable combination with a regulatory element and optionally a reporter gene.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: March 12, 2019
    Assignees: EMORY UNIVERSITY, CHILDREN'S HEALTHCARE OF ATLANTA, INC.
    Inventors: Martin L. Moore, Anne Hotard
  • Patent number: 10214564
    Abstract: A pharmaceutical composition for use in killing and/or inhibiting the growth and/or proliferation of a microorganism in a subject in need thereof, or for treating a subject afflicted with a microbial infection is disclosed. The composition comprises: (a) an effective amount of an isolated peptide, wherein the peptide comprises the arginine-rich carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an antimicrobial activity; and (b) a pharmaceutically acceptable carrier. The peptide exhibits an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: February 26, 2019
    Assignee: Academia Sinica
    Inventors: Chiaho Shih, Heng-Li Chen, Pei-Yi Su
  • Patent number: 10130697
    Abstract: The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: November 20, 2018
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Shinji Watanabe, Tokiko Watanabe, Yoshihiro Kawaoka
  • Patent number: 9821016
    Abstract: The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: November 21, 2017
    Assignee: Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
    Inventors: Ulrich Manfred Lauer, Michael Bitzer, Martina Zimmermann, Sorin Armeanu-Ebinger, Sascha Bossow, Wolfgang Neubert
  • Patent number: 9702016
    Abstract: Unique Avian Nephritis Virus (ANV) nucleic acid sequences have been determined. Primers and probes have been developed using the isolated nucleic acid sequences and a reverse transcription PCR has been developed to detect the presence of ANV in commercial flocks. Furthermore, use of the nucleic acid sequences and amino acids sequences encoded therefrom and antibodies to said amino acids is discussed.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: July 11, 2017
    Assignee: Agri-food and Biosciences Institute
    Inventors: Danny Todd, Victoria Smyth, Brian Adair
  • Patent number: 9526777
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: December 27, 2016
    Assignees: The United States of America as Represented by the Department of Health and Human Services, Glaxosmithkline Biologicals SA
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 9474798
    Abstract: A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well the resulting virus and vaccines with the virus.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: October 25, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Tokiko Watanabe, Yoshihiro Kawaoka
  • Patent number: 9255126
    Abstract: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: February 9, 2016
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John M. Polo, Silvia Perri, Kent Thudium, Zequn Tang
  • Patent number: 9180162
    Abstract: The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 10, 2015
    Assignee: Vical Incorporated
    Inventors: Gary G. Hermanson, Andrew J. Geall, Mary Kopke Wloch
  • Patent number: 9175269
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: November 3, 2015
    Assignees: TORAY INDUSTRIES, INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
  • Patent number: 9101561
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2ORF2 protein, and immunogenic compositions comprising PCV2ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2ORF2 protein, or an immunogenic composition comprising PCV2ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: August 11, 2015
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
  • Publication number: 20150140103
    Abstract: The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in Bombyx mori, a vector comprising the nucleic acid, Bombyx mori comprising the vector, and a method for producing a vaccine in which they are used.
    Type: Application
    Filed: July 23, 2013
    Publication date: May 21, 2015
    Inventors: Kazumichi Kuroda, Shigeo Sugita, Kuniaki Nerome, Reiko Nerome
  • Publication number: 20150140025
    Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski
  • Publication number: 20150141616
    Abstract: Intermolecular disulfide stabilized foldon polypeptides are provided.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Yuan Lu, James R. Swartz
  • Publication number: 20150132260
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Publication number: 20150132332
    Abstract: Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism.
    Type: Application
    Filed: January 21, 2015
    Publication date: May 14, 2015
    Inventors: YIMING SHAO, LIANXING LIU, RONGXIAN SHEN
  • Publication number: 20150132330
    Abstract: Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.
    Type: Application
    Filed: September 19, 2012
    Publication date: May 14, 2015
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Natalie Pica, Dirk Eggink, Rafael A. Medina-Silva, Rong Hai
  • Publication number: 20150133530
    Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 14, 2015
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-Mckenna
  • Patent number: 9029117
    Abstract: Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: May 12, 2015
    Assignee: Deutsches Krebsforschungzentrum
    Inventors: Jürg Nüesch, Nadja Thomas, Claudia Plotzky, Jean Rommelaere
  • Publication number: 20150118201
    Abstract: The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 30, 2015
    Inventors: Xiao Xiao, Lin Yang
  • Patent number: 9017694
    Abstract: The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: April 28, 2015
    Assignee: MedImmune, LLC
    Inventors: Hong Jin, Zhongying Chen
  • Patent number: 9017659
    Abstract: Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: April 28, 2015
    Assignee: Epeius Biotechnologies Corporation
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • Patent number: 9017695
    Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule. Also disclosed are particles and compositions that include the disclosed chimeric therapeutics.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: April 28, 2015
    Assignee: Biomed Realty, L.P.
    Inventors: Miguel de los Rios, Stephanie de los Rios
  • Patent number: 9018444
    Abstract: The present invention is to provide a novel non-diffusing plant virus vector wherein virus vector infection and proliferation are possible only in a recombinant plant transformed with a gene necessary for viral proliferation, thereby enabling avoidance of unintended diffusion of a recombinant virus, a selective and specific expression system therefor, and a method of expression thereof which comprises combining a non-diffusing virus vector lacking a gene involved in intercellular movement of a cucumber mosaic virus (CMV) genome and a transgenic plant transformed with the lacked gene involved in intercellular movement for the non-diffusing virus vector to establish infection and proliferation selectively and specifically in the transgenic plant.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: April 28, 2015
    Assignees: National Institute of Advanced Industrial Science and Technology, The Hokuren Federation of Agricultural Cooperatives, National University Corporation Hokkaido University
    Inventors: Noriho Fukuzawa, Takeshi Matsumura, Noriko Itchoda, Takeaki Ishihara, Chikara Masuta
  • Patent number: 9011873
    Abstract: The present invention relates to nucleic acids encoding mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 21, 2015
    Assignees: Los Alamos National Security, LLC, Duke University, Beth Israel Deaconess Medical Center, The University of Alabama at Birmingham Research Foundation
    Inventors: Bette T. Korber, William Fischer, Hua-Xin Liao, Barton F. Haynes, Norman Letvin, Beatrice H. Hahn
  • Patent number: 9012618
    Abstract: The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: April 21, 2015
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Nancy Sullivan, Bimal Chakrabarti, Zhi-Yong Yang, Maria Grazia Pau, Jaap Goudsmit, Gary Nabel
  • Patent number: 9011876
    Abstract: The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when administered to a subject but substantially retain the antigenic and immunogenic properties of wild-type RSV.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: April 21, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary K. Yagodich, Michael P. Citron, Daniel J. Distefano, Daniel L. Krah, Xiaoping Liang
  • Patent number: 9012214
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, the recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against the RNA virus or against both measles virus and against the RNA virus. It also relates to the use of the recombinant measles virus for the preparation of immunogenic compositions.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: April 21, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Clarisse Lorin, Lucile Mollet, Frédéric Delebecque
  • Publication number: 20150104475
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Application
    Filed: July 5, 2013
    Publication date: April 16, 2015
    Applicant: The Ohio State University
    Inventor: Daral John Jackwood
  • Publication number: 20150105290
    Abstract: The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Robert Purcell, Jens Bukh
  • Publication number: 20150104476
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: September 16, 2014
    Publication date: April 16, 2015
    Applicant: CUREVAC GMBH
    Inventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
  • Publication number: 20150104480
    Abstract: A method of producing a virus like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, or portion of the plant. The first nucleic acid comprises a first regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a structural virus protein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a channel protein, for example but not limited to a proton channel protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 16, 2015
    Inventors: Marc-Andre D'Aoust, Manon Couture, Louis-Philippe Vezina
  • Patent number: 9005961
    Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain, for example, the Schwarz strain. It also concerns the preparation of infectious recombinant viruses and immunogenic compositions using the cDNA.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: April 14, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Fréderic Tangy, Chantal Combredet, Valérie Labrousse-Najburg, Michel Brahic
  • Patent number: 9005925
    Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also contains the preparation of immunogenic compositions using said cDNA.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: April 14, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Chantal Combredet, Valérie Labrousse-Najburg, Michel Brahic
  • Patent number: 9006411
    Abstract: The present invention provides a lentiviral vector system having a higher titer, while sustaining an excellent retrograde transport ability, particularly, in the brain. The present invention also provides a kit for preparing a retrograde transport viral vector comprising: (1) a packaging plasmid containing the gag gene and the pol gene of HIV-1; (2) a packaging plasmid containing an accessory gene of HIV-1; (3) a transfer plasmid containing an target gene (a transgene); and (4) an envelope plasmid containing, as an envelope gene, a gene encoding a fused polypeptide comprising a fused extracellular domain consisting of the N-terminal region of an extracellular domain of rabies virus glycoprotein (RV-G) and the C-terminal region of an extracellular domain of vesicular stomatitis virus glycoprotein (VSV-G), a transmembrane domain of RV-G or VSV-G, and an intracellular domain of VSV-G, and the like.
    Type: Grant
    Filed: November 25, 2011
    Date of Patent: April 14, 2015
    Assignee: Japan Science and Technology Agency
    Inventor: Kazuto Kobayashi
  • Publication number: 20150098965
    Abstract: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 9, 2015
    Inventor: JANET K. YAMAMOTO
  • Patent number: 9000139
    Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: April 7, 2015
    Assignee: Genexine, Inc.
    Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
  • Patent number: 9000141
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: April 7, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • Publication number: 20150093403
    Abstract: The invention is directed to a isolated a canine circoviruses associated with canine respiratory and gastrointestinal disease, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to antibodies against antigens from canine circoviruses. The invention also relates to iRNAs which target nucleic acid sequences of the canine circovirus. The invention is related to methods for detecting the presence or absence of canine circoviruses in an animal. The invention is also related to immunogenic compositions for inducing an immune response against canine circoviruses in an animal.
    Type: Application
    Filed: April 3, 2013
    Publication date: April 2, 2015
    Inventors: W. Ian Lipkin, Amit Kapoor, Edward J. Dubovi
  • Publication number: 20150093413
    Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
    Type: Application
    Filed: February 15, 2013
    Publication date: April 2, 2015
    Applicant: CureVac GmbH
    Inventors: Andreas Thess, Thomas Schlake, Jochen Probst
  • Publication number: 20150093404
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Application
    Filed: October 2, 2014
    Publication date: April 2, 2015
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Luis Alejandro HERNANDEZ, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN, Gregory HAIWICK
  • Patent number: 8993744
    Abstract: Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be used as vaccines for immunization against dengue virus infection. In some cases, the vaccine includes a virus-like particle containing the universal dengue virus E protein, or fragment thereof, or the vaccine is a DNA molecule encoding the VLP.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: March 31, 2015
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Nikolaos Vasilakis
  • Patent number: 8993839
    Abstract: Described herein are viral amplicon-based protein expression systems and methods useful for producing heterologous proteins, such as enzymes, by agroinfiltration. The methods involve producing an Agrobacterium with a Ti plasmid encoding a heterologous protein, infecting plant cells with the Agrobacterium, allowing expression of the heterologous protein, and recovering the heterologous protein from the plant cells. In one embodiment, the protein produced is an endoglucanase.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: March 31, 2015
    Assignee: The Regents of the University of California
    Inventors: Minsook Hwang, Benjamin E. Lindenmuth, Karen A. McDonald, Abhaya M. Dandekar, Bryce W. Falk, Sang-Kyu Jung, Nathaniel J. Kingsbury
  • Publication number: 20150086580
    Abstract: Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 26, 2015
    Inventors: Steven Foung, Zhen-Yong Keck, Thomas R. Fuerst
  • Publication number: 20150086577
    Abstract: Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus Phlebovirus (family Bunyaviridae) with a proposed name of Heartland virus (HRTLV). Provided herein are nucleotide and amino acid sequences of the Phlebovirus isolates, primers and probes that specifically hybridize with the Phlebovirus isolates, and antibodies specific for the Phlebovirus proteins. Also provided are detection assays using the Phlebovirus nucleic acid molecules, proteins, probes, primers and antibodies. Further provided are recombinant Phleboviruses and their use for eliciting an immune response in a subject.
    Type: Application
    Filed: March 22, 2013
    Publication date: March 26, 2015
    Applicant: The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Laura K. McMullan, Cynthia Goldsmith, Aubree Kelly, William L. Nicholson, Stuart T. Nichol
  • Publication number: 20150086636
    Abstract: The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). Some of the methods involve delivering genes to cells using gene delivery or other delivery techniques known in the art in order to inhibit myostatin. Examples of genes to be delivered are genes encoding proteins such as Follistatin, Follistatin-related gene-1 (FLRG-1), growth differentiation factor associated protein-1 (GASP-1) and myostatin precursor propeptide. The genes can be delivered using, for example, a recombinant Adeno-associated virus (rAAV), lentivirus or equine-associated virus capable of infecting the cells. Following introduction, the genes are expressed in the cell body of the infected cell and the encoded proteins are secreted systemically.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 26, 2015
    Inventors: Brian K. Kaspar, Jerry R. Mendell
  • Publication number: 20150079121
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acid are disclosed that comprise the sequences that encodes consensus RSV F protein or immunogenic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Method of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.
    Type: Application
    Filed: April 10, 2013
    Publication date: March 19, 2015
    Inventors: David B. Weiner, Daniel Choo, Karuppiah Muthumani, Nyamekye Obeng-Adjei, Veronica Scott
  • Patent number: 8980545
    Abstract: Presented herein is the discovery of a new human picornavirus, Cosavirus (previously termed Dekavirus), methods of detecting the Cosavirus and diagnosing Cosavirus infection, methods of treating or preventing Cosavirus infection, and methods for identifying anti-Cosavirus compounds.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: March 17, 2015
    Assignee: Blood Systems, Inc.
    Inventors: Eric Delwart, Amit Kapoor, Joseph Victoria
  • Patent number: 8981073
    Abstract: Disclosed are an HCV gene having higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b, an RNA replicon having this gene, a cell infected with this RNA replicon, which cell allows replication of HCV, and an HCV particle. The hepatitis C virus gene encodes an amino acid sequence wherein the 979th amino acid is threonine; the 1804th amino acid is leucine; and the 1966th amino acid is lysine. An HCV gene which can propagate in vitro and has higher replication efficiency and higher reinfection efficiency than the known HCV gene of genotype 1b was provided.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: March 17, 2015
    Assignee: Advanced Life Science Institute, Inc.
    Inventors: Kenichi Mori, Noboru Maki, Hiromi Fukai
  • Patent number: 8980280
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: March 17, 2015
    Assignees: Merial, Inc., Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
    Inventors: Herve Poulet, Thierry Heidmann